Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05401786 | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | PHASE2 | ACTIVE NOT_RECRUITING | 54 | — | — | Jan 3, 2023 | Jun 1, 2026 | Mar 12, 2026 | 1 | Netherlands |
Number of participants with complete response or partial response within the first 6 months or stable disease lasting for minimum 6 months
| Arm | Type | Description |
|---|---|---|
| Anti-CTLA-4, SBRT and PD1 | EXPERIMENTAL | Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions. Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg intravenously every 3 weeks) until disease progression, unacceptable toxicity, patient request for discontinuation, or up to 2 years of treatment |
| Name | Type | Description |
|---|---|---|
| Ipilimumab | DRUG | Anti-CTLA-4 |
| Cemiplimab | DRUG | PD-1 inhibition |
| SBRT | RADIATION | Stereotactic Body Radiotherapy |
Inclusion Criteria: 1. Have proven diagnosis of recurrent advanced NSCLC, irrespective of histological subtype. 2. Be willing and able to provide written informed consent/assent for the trial. 3. Must still have measurable disease based on RECIST 1.1 after application of study SBRT. Lesions that we...